New view on advanced renal cancer targeted therapies efficacy – controversies
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
During the last few years the strong progress on new therapies in advanced/metastatic renal cell carcinoma has been observed. It is mostly related to understanding of significant renal cell cancer molecular basics. Previously, the standard of care for patients with advanced disease was cytokine therapy, such as interleukin-2 (IL-2) or interferon alpha. The efficacy of cytokines therapy is limited and both drugs are associated with significant toxicity. New therapies, called targeted therapies, have been approved based on randomized clinical trials, in accordance with the american Food and Drug Administration agency and the European Medicines Agency directives. Targeted therapies include vascular endothelial growth factor receptor tyrosine kinase inhibitors (sorafenib, sunitinib, pazopanib), monoclonal vascular endothelial growth factor antibodies (bevacizumab) and seronine-threonine kinase mTOR inhibitors (temsirolimus, everolimus) (mTOR, mammalian target of rapamycin). Based on mentioned clinical trials the efficacy of targeted therapies was demonstrated first of all on the basis of significant progression free survival improvement. Until now the gold standard of oncology treatment efficacy was the overall survival. The controversies and most recent reports on mentioned above end points with reference to efficacy results of medications used in advanced/metastatic renal cell cancer treatment are presented in this review.
Authors and Affiliations
Cezary Szczylik
Keywords
Related Articles
- EP ID EP53088
- DOI -
- Views 268
- Downloads 0
Selected aspects of gastrointestinal stromal tumors management with tyrosine kinase inhibitors
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract that most frequently affect the stomach and small intestine. In the past these tumors may have been misclassifi...
„D-dimerosis” among the patients with the cancer it is always needed to be treated?
The risk of thromboembolic disease increases in malignant tumors. D-dimer is a product of fibrin degradation. Its concentration rises in neoplasms, but also in another diseases characterized by activation of clotting and...
The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objecti...
Antiproliferative effect of somatostatin analogs - PROMID study
Tuberus sclerosis